Ken Griffin Ocuphire Pharma, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$1.51 - $2.23 $6,342 - $9,366	-4,200 Reduced 67.74%	2,000 $3,000
Q1 2024 May 15, 2024	BUY	$1.89 - $3.27 $7,938 - $13,734	4,200 Added 210.0%	6,200 $12,000
Q4 2023 Feb 14, 2024	SELL	$2.59 - $3.64 $23,051 - $32,396	-8,900 Reduced 81.65%	2,000 $6,000
Q3 2023 Nov 14, 2023	BUY	$3.35 - $4.33 $9,045 - $11,691	2,700 Added 32.93%	10,900 $36,000
Q2 2023 Aug 14, 2023	BUY	$3.63 - $6.38 $23,958 - $42,108	6,600 Added 412.5%	8,200 $35,000
Q1 2023 May 15, 2023	SELL	$3.01 - $3.85 $18,662 - $23,870	-6,200 Reduced 79.49%	1,600 $6,000
Q4 2022 Feb 14, 2023	BUY	$2.04 - $3.53 $15,912 - $27,534	7,800 New	7,800 $27,000

2.54M

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $24.3M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.